213 related articles for article (PubMed ID: 34822072)
1. Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting M
Xiao T; Cui M; Zheng C; Zhang P; Ren S; Bao J; Gao D; Sun R; Wang M; Lin J; Zhang L; Li M; Li D; Zhou H; Yang C
Inflammation; 2022 Jun; 45(3):1076-1088. PubMed ID: 34822072
[TBL] [Abstract][Full Text] [Related]
2.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
3. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis.
Xiao T; Wei Y; Cui M; Li X; Ruan H; Zhang L; Bao J; Ren S; Gao D; Wang M; Sun R; Li M; Lin J; Li D; Yang C; Zhou H
Phytomedicine; 2021 Oct; 91():153704. PubMed ID: 34419736
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
[TBL] [Abstract][Full Text] [Related]
5. Theaflavin 3-gallate inhibits the main protease (M
Chauhan M; Bhardwaj VK; Kumar A; Kumar V; Kumar P; Enayathullah MG; Thomas J; George J; Kumar BK; Purohit R; Kumar A; Kumar S
Sci Rep; 2022 Jul; 12(1):13146. PubMed ID: 35908093
[TBL] [Abstract][Full Text] [Related]
6. Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease.
Hengphasatporn K; Wilasluck P; Deetanya P; Wangkanont K; Chavasiri W; Visitchanakun P; Leelahavanichkul A; Paunrat W; Boonyasuppayakorn S; Rungrotmongkol T; Hannongbua S; Shigeta Y
J Chem Inf Model; 2022 Mar; 62(6):1498-1509. PubMed ID: 35245424
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of SARS-CoV 3C-like protease with baicalein.
Feng J; Li D; Zhang J; Yin X; Li J
Biochem Biophys Res Commun; 2022 Jun; 611():190-194. PubMed ID: 35490659
[TBL] [Abstract][Full Text] [Related]
8. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
9. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
10. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
[TBL] [Abstract][Full Text] [Related]
11. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
[TBL] [Abstract][Full Text] [Related]
14. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
15. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
Zhang K; Wang T; Li M; Liu M; Tang H; Wang L; Ye K; Yang J; Jiang S; Xiao Y; Xie Y; Lu M; Zhang X
Eur J Med Chem; 2023 Sep; 257():115487. PubMed ID: 37257212
[TBL] [Abstract][Full Text] [Related]
16. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
[TBL] [Abstract][Full Text] [Related]
17. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
18. Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals.
Xu YS; Chigan JZ; Li JQ; Ding HH; Sun LY; Liu L; Hu Z; Yang KW
Bioorg Chem; 2022 Jul; 124():105799. PubMed ID: 35462235
[TBL] [Abstract][Full Text] [Related]
19. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
20. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
